The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V84617 | PB49673382 | 2763495-65-2 | |
|
V101427 | Pemivibart | Pemivibart is a human IgG1 lambda2 monoclonal antibody targeting SARS-CoV-2. | |
|
V41524 | PF-00835231 (PF-835231) | 870153-29-0 | PF-00835231 (PF-835231) is a potent 3CLpro [main protease (Mpro)] inhibitor developed by Pfizer for COVID-19treatment. |
|
V97163 | PF-07957472 | 3041047-51-9 | PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. |
|
V105464 | Pixatimod free acid | 1144617-49-1 | Pixatimod free acid (PG545 free acid) is a heparin sulfate analog with heparinase inhibitory activity. |
|
V54411 | PLpro-IN-1 | 1093070-10-0 | PLpro-IN-1 (Compound 2) is a SARS-CoV PLpro inhibitor (IC50= 8.7 μM). |
|
V89674 | PLpro-IN-2 | PLpro-IN-2 (Compound 16) is a SARS-CoV-2 papain-like protease (PLpro) inhibitor with IC50 of 0.25 μM. | |
|
V89703 | PLpro-IN-3 | PLpro-IN-3 (compound 26R) is a potent papain (PLpro) inhibitor with IC50 of 1.0 μM. | |
|
V98645 | PLpro-IN-5 | 3009839-42-0 | PLpro-IN-5 (Compound 21) is a PLPro protease inhibitor with IC50 of 91.14 nM. |
|
V98012 | PLpro-IN-6 | 3041046-04-9 | PLpro-IN-6 (Compound 6) is an inhibitor of papain-like protease (PLpro) with an IC50 value of 0.019 μM for SARS CoV2 PLpro. |
|
V94469 | PLpro-IN-7 | 3046158-99-7 | PLpro-IN-7 (Compound 83) is a novel papain-like protease (PLpro) inhibitor with IC50 of 3 nM. |
|
V93208 | PLpro-IN-8 | PLpro-IN-8 (Compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. | |
|
V54425 | PLpro/RBD-IN-1 | 1282451-83-5 | PLpro/RBD-IN-1 (Compound 5) is a dual (bifunctional) inhibitor of SARS-CoV-2 PLpro and spike protein RBD, with IC50 of 7.197 μM and 8.673 μM respectively. |
|
V76079 | Propiolactone (β-propiolactone; 2-Oxetanone; Betaprone) | 57-57-8 | Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. |
|
V97383 | PSB-21110 | PSB-21110 is an irreversible SARS-CoV-2 Mpro inhibitor with an EC50 value of 2.68 nM. | |
|
V39234 | Quipazine (2-(1-piperazinyl)quinoline) | 4774-24-7 | Quipazine is a 5-HT agonist that displaces 5-HT3R in rat endothelium with a Ki of 1.4 nM for [3H]GR65630. |
|
V39265 | Quipazine dimaleate | 150323-78-7 | Quipazine dimaleate is a 5-HT agonist, displacing 5-HT3R in rat endothelium [3H]GR65630 with a Ki of 1.4 nM. |
|
V85294 | RBT-9 | 123307-75-5 | |
|
V39194 | RdRP-IN-2 | 2863657-16-1 | RdRP-IN-2 is an RNA-dependent RNA polymerase (RdRp) inhibitor. |
|
V81279 | RdRP-IN-7 | RdRP-IN-7 is an RNA-dependent RNA polymerase (RdRP) inhibitor that shows inhibition of SARS-CoV-2 infection with IC50 of 8.2 μM, an IC90 of 14.1 μM, and a CC90 of 79.1 μM . |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
